750-3 The Role of Triglyceride-Rich Lipoprotein Families in the Progression of Coronary Artery Atherosclerotic Lesions  by Hodis, Howard N. et al.
JACC February 1995
DNA synthesis in smooth muscle cells (SMC). Due to its complex chemical
structure it has been difficult to identify the active mitogenic components
of ox-LDL. Within the first 48 hours of oxidation we found a 75% reduction
of lecithin while lysolecithin was increased 25-fold, lipid peroxide levels in-
creased 8-fold and aldehydes increased 20-fold as determined by the thiobar-
bituric reactive (TBAR) assay. To identify the components of ox-LDL respon-
sible for stimulation of DNA synthesis, human arterial SMC were exposed
to various peroxides, aldehydes, and phospholipids and DNA synthesis was
analyzed by autoradiography using radioactive thymidine in corporation in
nuclei.
Substance % labelled nuclei ± SD p vs Ctl
Control (1% serum) 23.3 3.5
LDL 5/lg/ml 31.0 5.5 NS
ox-LDL 5 /lg/ml 75.Z 78 0.005
lysolecithin 10 /lM 75.3 45 0.003
LDL 5 /lg/ml + PhosholipaseAZ 41 U/ml 730 3.6 00001
HZOZ ZOO /lM 39.0 1.7 0.01
The DNA synthesis increased 3 fold with ox-LDL and this effect was repli-
cated by substituting lysolecithin or LDL + Phospholipase Az (to gener-
ate lysolecithin) for ox-LDL. Peroxides also had a modest stimulatory ef-
fect. Malondialdehyde, oxysterols, Iysophosphatidylserine, phosphatidylser-
ine, lecithin, sphingomyelin and sphingosine were without effect. Conclu-
sion: The present results indicate that the growth stimulatory effect of ox-
LDL is due to the formation of lysolecithin and peroxides during the oxidation
process.
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Eicosapentaenoic Acid and Docosahexaenoic Acid in
Fish Oils Reverse the Thromboxane Az Induced
Vascular Smooth Muscle Cell Proliferation
Rajbabu Pakala, Rajashree Pakala, Claude R. Benedict. University of Texas Medical
School, Houston, Texas
There is conflicting data to indicate whether omega-3 fatty acids present in
dietary fish oil supplementation can prevent the development of restenosis
following angioplasty. Thromboxane Az (TxAz) released at sites of vascular
injury due to platelet aggregation, is a known mitogen for vascular smooth
muscle cells (SMC). This may playa role in the development of resteno-
sis follOWing angioplasty. We examined whether the omega-3 fatty acids,
eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) present in fish
oils, can prevent TxAz induced SMC proliferation. Canine primary aortic SMC
were grown in 1% fetal bovine serum with different concentrations of TxAz(U46619) and with 3.3 /lM each of EPA, DHA, linolenic acid (LOA) (n-3), oleic
acid (OA) (n-9) or without any fatty acids (control I. and then 3H-thymidine in-
corporated into the DNA of SMC was measured. We used LOA and OA as
non omega-3 unsaturated fatty acids for comparison in our study.
The data shows that the TxAz induced SMC proliferation is reversed by
EPA and DHA and not by LOA or OA.
Conclusion: This suggests that omega-3 fatty acids, EPA and DHA, may
attenuate the development of restenosis following coronary angioplasty by
inhibiting the TxAz induced SMC proliferation.
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The Role of Triglyceride-Rich Lipoprotein Families in
the Progression of Coronary Artery Atherosclerotic
Lesions
Howard N. Hodis, Wendy J. Mack, Carolyn Knight-Gibson, Petar Alaupovic.
University ofSouthern California, Los Angeles, CA; Oklahoma Medical Research
Foundation, Oklahoma City, OK
The affect of triglyceride-rich lipoprotein particles on the progression of coro-
nary artery atherosclerotic lesions is not known. In a subset of 270 subjects
in the Monitored Atherosclerosis Regression Study, lovastatin significantly
reduced apolipoprotein (Apo) B and cholesterol-rich lipoprotein (Lp) B levels
without significantly affecting triglyceride-rich Lp (LpBc) particles, Lp-B:C,
Lp-B:C:E, and Lp-AII:B:C:D:E. This differential affect of lovastatin on apoB-
containing lipoproteins offered the opportunity to determine the indepen-
dent relationship of LpB and specific LpBc particles on the progression of
coronary artery disease. Subjects were randomized to lovastatin 40 mg b.i.d.
or placebo for 2 years and progression determined by quantitative coronary
angiography. There were 15 progressors (P) and 15 nonprogressors (NP) in
the lovastatin group and 13 P and 13 NP in the placebo group. In the placebo
group, there was a significant difference between Pand NP (mean ± SEM) in
plasma triglyceride (259 ± 33.6 vs 142.9 ± 20.8, P = 0.003), apoCIII(16.1 ±
1.2 vs 11.9 ± 0.7, P = 0.021. and apoB (127.4 ± 5.9 vs 112.4 ± 4.7, P = 0.04)
levels. In the lovastatin group, there was a significant difference between P
and NP in Lp-AII:B:C:D:E (8.4 ± 1.3 vs 5.0 ± 0.9, p = 0.02) and apoAI (119.3 ±
61 vs 134.0 ± 3.6, p = 0.021 levels. However. there was no significant differ-
ence in Lp-B:C or Lp-B:C:E levels between P and NP. These data confirm the
atherogenic potential of LpB particles and show that after reduction of LpB
particles to below 75 mg/dL in the lovastatin group. LpBc particles in gen-
eral, and Lp-AII:B:C:D:E specifically, play an important role in progression of
coronary artery disease. The possible reason for the atherogenic potential
of Lp-AII: B:C: D: E relative to other LpBc particles may be related to its lower
reactivity toward lipoprotein lipase and therefore. longer residence time in
the circulation.
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1750-41 The Influence of Lipoprotein(a) Levels on the
Angiograpic Course of Coronary Atherosclerosis in
Patients with High and Low LDL·C
Jeroen Vos, Gilbert R. Thompson I, Pim J. de Feyter, Geert Boerma, Jean
M. Dumont, MMS Investigators. Thoraxcenter. Erasmus University Rotterdam, NL;
1 Hammersmith Hospital, London. UK
Introduction: Previous reports have indicated that a high level of Lp(a) is an
independent risk factor for coronary artery disease. Data from angiographic
regression trials suggest that the adverse effect of high Lp(a) can be amelio-
rated by lowering LDL-C.
Methods: Patients with mild coronary atherosclerosis and with total
cholesterol of 6.43 ± 0.75 mmolll, LDL-C 4.40 ± 0.69 mmolll, and LP(a)
25.4 ± 27.6 mgldl were treated with placebo (N = 167) or simvastatin 20
mg daily (N = 178). Quantitative Coronary Angiography was performed at
oand 4 years. Both the changes in mean lumen diameter (diffuse coronary
atherosclerosisI. and minimum lumen diameter and diameter stenosis (focal
coronary atherosclerosis) were assessed. Angiographic changes were strat-
ified by Lp(allevel and by LDL-C level during the trial.
Results: Simvastatin lowered TC by 23%, LDL-C by 31 %, Lp(a) was not
influenced. The angiographic changes over 4 years were as follows:
LDL-C < 3.5 >3.5 mmol/l P
Mininum Diameter (mm):
Lp(a) <35 mg/dl -0.05 ± 0.Z4 -0.15 ± 027 0.005
2::35 mg/dl -001 ± 0.Z4 -0.05 ± 0.Z5 ns
Diameter stenosis (%):
Lp(a) <35 mg/dl 0.5 ± 78 4.1 ± 95 0001
2::35 mg/dl 0.5 ± 67 Z.8 ± 7.9 ns
Mean Lumen Diameter (mm):
Lp(a) <35 mg/dl -0.05 ± OZ4 -0.09 ± 024 ns
>35 mg/dl 0.01 ± OZ5 -0.01 ± 0.Z4 ns
Conclusions: our findings contrast with previous reports and show that
high Lp(a) is associated with more progression of focal atherosclerosis (but
not diffuse) when LDL-C is low. Lowering LDL-C was more beneficial when
Lp(a) was low.
